NCT03666559View on ClinicalTrials.gov

Treatment With Azacitidine of Recurrent Gliomas With IDH1/2 Mutation

PHASE2Active, not recruitingINTERVENTIONAL

Enrollment

8

Participants

Timeline

Start Date

September 22, 2020

Primary Completion Date

February 23, 2023

Study Completion Date

March 23, 2024

Conditions

Recurrent IDH1/2 Mutated Glioma

Interventions

DRUG

Azacitidine

Chemotherapy

Trial Locations (1)

75013

Pitie Salpetriere Hospital, Paris

All Listed Sponsors

lead

Assistance Publique - Hôpitaux de Paris

OTHER